Literature DB >> 15975071

New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease?

Marjorie Maillet1, Sylvain J Robert, Frank Lezoualc'h.   

Abstract

The serotonin 5-HT4 receptor mediates many physiological effects in the central nervous system. The recent molecular identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the physiological roles of these G protein-coupled-receptors in neurones. With respect to neurodegenerative disorders, it is suggested that 5-HT4 agonists may represent a new avenue for the treatment of Alzheimer's disease. This mini-review will focus on recent in vitro and in vivo pharmacological and biochemical studies showing the involvement of 5-HT4 receptors in cognitive processes and the amyloid precursor protein processing. The potential use of 5-HT4 agonists for the treatment of AD will be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15975071     DOI: 10.2174/1567205043332252

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

Review 1.  Tailoring of membrane proteins by alternative splicing of pre-mRNA.

Authors:  Kathleen F Mittendorf; Catherine L Deatherage; Melanie D Ohi; Charles R Sanders
Journal:  Biochemistry       Date:  2012-06-29       Impact factor: 3.162

2.  5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.

Authors:  M Cachard-Chastel; F Lezoualc'h; I Dewachter; C Deloménie; S Croes; H Devijver; M Langlois; F Van Leuven; S Sicsic; A M Gardier
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

3.  New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.

Authors:  Lucie Rivail; Mireille Giner; Monique Gastineau; Magali Berthouze; Jean-Louis Soulier; Rodolphe Fischmeister; Frank Lezoualc'h; Bernard Maigret; Sames Sicsic; Isabelle Berque-Bestel
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

4.  Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.

Authors:  Patrick D Roberts; Athan Spiros; Hugo Geerts
Journal:  Alzheimers Res Ther       Date:  2012-11-26       Impact factor: 6.982

5.  Understanding the Molecular Basis of 5-HT4 Receptor Partial Agonists through 3D-QSAR Studies.

Authors:  Alejandro Castro-Alvarez; Emigdio Chávez-Ángel; Ronald Nelson
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

Review 6.  From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.

Authors:  Jazmín Alarcón-Espósito; Michael Mallea; Julio Rodríguez-Lavado
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.